Study to Evaluate the Efficacy of N-acetylcysteine (NAC) in the Treatment of the Common Cold and Cough

• Status: Completed
• Trial end date: 2015-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to improve knowledge regarding the initial effectiveness of N-acetylcysteine (NAC) on cold and cough symptoms.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis
• Treatments: Acetylcysteine; N-monoacetylcystine

Criteria

Inclusion Criteria:

• Cold/URTI symptoms occurring no more than 4 days

• cough due to a cold or acute viral (URTI) with an onset of no more than 3 days

• cough frequency with specified cut-off

Exclusion Criteria:

• A subchronic, or chronic cough (cough duration > 2 months) due to any condition other than a cold/URTI

• Diagnosed as suffering from any pulmonary conditions associated with cough, e.g., chronic obstructive pulmonary disease (COPD), acute or chronic bronchitis, asthma, cystic fibrosis

• Taking any medications known to induce cough

• Fever of greater than 39°C (102°F) orally

• Complication of the common cold like otitis media, severe sinusitis, or pneumonia

• Other protocol-defined inclusion/exclusion criteria may apply